Back to Search Start Over

NCCN GuidelinesĀ® Insights: Gastrointestinal Stromal Tumors, Version 2.2022.

Authors :
von Mehren M
Kane JM
Riedel RF
Sicklick JK
Pollack SM
Agulnik M
Bui MM
Carr-Ascher J
Choy E
Connelly M
Dry S
Ganjoo KN
Gonzalez RJ
Holder A
Homsi J
Keedy V
Kelly CM
Kim E
Liebner D
McCarter M
McGarry SV
Mesko NW
Meyer C
Pappo AS
Parkes AM
Petersen IA
Poppe M
Schuetze S
Shabason J
Spraker MB
Zimel M
Bergman MA
Sundar H
Hang LE
Source :
Journal of the National Comprehensive Cancer Network : JNCCN [J Natl Compr Canc Netw] 2022 Nov; Vol. 20 (11), pp. 1204-1214.
Publication Year :
2022

Abstract

Gastrointestinal stromal tumors (GIST) are the most common type of soft tissue sarcoma that occur throughout the gastrointestinal tract. Most of these tumors are caused by oncogenic activating mutations in the KIT or PDGFRA genes. The NCCN Guidelines for GIST provide recommendations for the diagnosis, evaluation, treatment, and follow-up of patients with these tumors. These NCCN Guidelines Insights summarize the panel discussion behind recent important updates to the guidelines, including revised systemic therapy options for unresectable, progressive, or metastatic GIST based on mutational status, and updated recommendations for the management of GIST that develop resistance to specific tyrosine kinase inhibitors.

Details

Language :
English
ISSN :
1540-1413
Volume :
20
Issue :
11
Database :
MEDLINE
Journal :
Journal of the National Comprehensive Cancer Network : JNCCN
Publication Type :
Academic Journal
Accession number :
36351335
Full Text :
https://doi.org/10.6004/jnccn.2022.0058